Compare Stocks: COAG, CGON, ERAS, and MIRM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGON CG Oncology	$61.84 -0.9%	$72.83	$35.80 ▼ $80.97	$5.53B	0.28	1.09 million shs	1.10 million shs
COAG Hemab Therapeutics	$29.94 +0.5%	$41.66	$23.00 ▼ $55.42	$1.39B	N/A	642,318 shs	224,941 shs
ERAS Erasca	$14.70 -0.5%	$16.31	$2.11 ▼ $24.28	$5.17B	0.61	5.46 million shs	4.75 million shs
MIRM Mirum Pharmaceuticals	$79.96 +0.4%	$93.70	$63.23 ▼ $130.00	$5.19B	0.61	944,059 shs	975,113 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGON CG Oncology	-0.90%	-0.87%	-16.19%	-11.02%	+44.32%
COAG Hemab Therapeutics	+0.47%	+4.32%	-26.02%	-32.76%	+2,993,999,900.00%
ERAS Erasca	-0.54%	+4.11%	-9.03%	-22.71%	+509.96%
MIRM Mirum Pharmaceuticals	+0.43%	-0.84%	-17.35%	-31.87%	+9.12%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGON CG Oncology	$61.84 -0.9%	$72.83	$35.80 ▼ $80.97	$5.53B	0.28	1.09 million shs	1.10 million shs
COAG Hemab Therapeutics	$29.94 +0.5%	$41.66	$23.00 ▼ $55.42	$1.39B	N/A	642,318 shs	224,941 shs
ERAS Erasca	$14.70 -0.5%	$16.31	$2.11 ▼ $24.28	$5.17B	0.61	5.46 million shs	4.75 million shs
MIRM Mirum Pharmaceuticals	$79.96 +0.4%	$93.70	$63.23 ▼ $130.00	$5.19B	0.61	944,059 shs	975,113 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGON CG Oncology	-0.90%	-0.87%	-16.19%	-11.02%	+44.32%
COAG Hemab Therapeutics	+0.47%	+4.32%	-26.02%	-32.76%	+2,993,999,900.00%
ERAS Erasca	-0.54%	+4.11%	-9.03%	-22.71%	+509.96%
MIRM Mirum Pharmaceuticals	+0.43%	-0.84%	-17.35%	-31.87%	+9.12%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CGON CG Oncology	2.70	Moderate Buy	$87.50	41.49% Upside
COAG Hemab Therapeutics	2.75	Moderate Buy	$52.17	74.24% Upside
ERAS Erasca	2.64	Moderate Buy	$22.09	50.28% Upside
MIRM Mirum Pharmaceuticals	2.93	Moderate Buy	$147.88	84.94% Upside

Current Analyst Ratings Breakdown

Latest COAG, CGON, ERAS, and MIRM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/14/2026	MIRM Mirum Pharmaceuticals	Stifel Nicolaus Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$156.00
10/13/2026	MIRM Mirum Pharmaceuticals	Evercore Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform	$146.00
10/12/2026	MIRM Mirum Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$137.00 ➝ $152.00
10/12/2026	MIRM Mirum Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/12/2026	COAG Hemab Therapeutics	Rodman & Renshaw Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$56.00
10/12/2026	COAG Hemab Therapeutics	Rodman & Renshaw Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy
10/12/2026	MIRM Mirum Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$160.00 ➝ $184.00
10/12/2026	MIRM Mirum Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$195.00 ➝ $200.00
10/8/2026	MIRM Mirum Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Outperform	$135.00 ➝ $155.00
9/29/2026	MIRM Mirum Pharmaceuticals	Robert W. Baird Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Outperform	$123.00 ➝ $130.00
9/28/2026	MIRM Mirum Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$144.00

(Data available from 10/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CGON CG Oncology	$4.04M	1,356.81	N/A	N/A	$9.33 per share	6.63
COAG Hemab Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
ERAS Erasca	N/A	N/A	N/A	N/A	$1.05 per share	N/A
MIRM Mirum Pharmaceuticals	$618.07M	8.40	$0.05 per share	1,561.82	$6.12 per share	13.07

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CGON CG Oncology	-$160.99M	-$2.69	N/A	N/A	N/A	-3,602.68%	-25.20%	-23.98%	11/13/2026 (Estimated)
COAG Hemab Therapeutics	N/A	-$24.78	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ERAS Erasca	-$124.55M	-$0.95	N/A	N/A	N/A	N/A	-38.43%	-32.05%	11/11/2026 (Estimated)
MIRM Mirum Pharmaceuticals	-$23.36M	-$14.55	N/A	N/A	N/A	-139.18%	-36.28%	-8.54%	11/3/2026 (Estimated)

Latest COAG, CGON, ERAS, and MIRM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/11/2026	Q3 2026	ERAS Erasca	-$0.1301	N/A	N/A	N/A	N/A	N/A
11/3/2026	Q3 2026	MIRM Mirum Pharmaceuticals	-$0.4889	N/A	N/A	N/A	$178.06 million	N/A
8/11/2026	Q2 2026	COAG Hemab Therapeutics	-$0.63	-$0.80	-$0.17	-$0.80	N/A	N/A
8/11/2026	Q2 2026	ERAS Erasca	-$0.1114	-$0.14	-$0.0286	-$0.14	N/A	N/A
8/6/2026	Q2 2026	CGON CG Oncology	-$0.6642	-$0.90	-$0.2359	-$0.90	$0.36 million	$1.16 million
8/5/2026	Q2 2026	MIRM Mirum Pharmaceuticals	-$0.7425	-$1.06	-$0.3175	-$1.06	$166.33 million	$176.24 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CGON CG Oncology	N/A	N/A	N/A	N/A	N/A
COAG Hemab Therapeutics	N/A	N/A	N/A	N/A	N/A
ERAS Erasca	N/A	N/A	N/A	N/A	N/A
MIRM Mirum Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CGON CG Oncology	N/A	22.22	22.20
COAG Hemab Therapeutics	N/A	35.85	35.85
ERAS Erasca	N/A	8.29	8.29
MIRM Mirum Pharmaceuticals	1.28	2.86	2.74

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CGON CG Oncology	26.56%
COAG Hemab Therapeutics	N/A
ERAS Erasca	67.78%
MIRM Mirum Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
CGON CG Oncology	4.80%
COAG Hemab Therapeutics	N/A
ERAS Erasca	14.20%
MIRM Mirum Pharmaceuticals	8.32%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CGON CG Oncology	142	88.64 million	84.39 million	Optionable
COAG Hemab Therapeutics	59	46.71 million	N/A	N/A
ERAS Erasca	103	349.76 million	300.10 million	Optionable
MIRM Mirum Pharmaceuticals	433	64.93 million	59.53 million	Optionable

COAG, CGON, ERAS, and MIRM Headlines

Recent News About These Companies

Analysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (MIRM), Connect Biopharma Holdings (CNTB) and Helus Pharma (HELP)

1 hour ago | theglobeandmail.com

MIRM Stock Gets Reduced EPS Estimate from HC Wainwright

October 14 at 6:41 AM | marketbeat.com

Citigroup Forecasts Strong Price Appreciation for Mirum Pharmaceuticals (NASDAQ:MIRM) Stock

October 14 at 1:36 AM | americanbankingnews.com

Mirum Pharmaceuticals (NASDAQ:MIRM) Shares Down 6.4% - Here's What Happened

October 13 at 3:39 PM | marketbeat.com

Mirum's Livmarli Meets Phase III Goal in Ultra-Rare Liver Diseases

October 13 at 11:45 AM | zacks.com

Q3 EPS Forecast for Mirum Pharmaceuticals Reduced by Analyst

October 13 at 8:26 AM | marketbeat.com

Mirum Pharmaceuticals (NASDAQ:MIRM) Stock Gets Price Target Increase from Citigroup

October 12 at 5:17 PM | marketbeat.com

Mirum Pharmaceuticals Meets Primary Endpoint In Phase 3 LIVMARLI Study

October 12 at 3:01 PM | rttnews.com

Mirum Pharmaceuticals Reports Positive Phase 3 LIVMARLI Results; Plans FDA Filing In 2027

October 12 at 3:01 PM | rttnews.com

Mirum Pharmaceuticals Says Livmarli Meets Primary Endpoint in Phase 3 Liver Disease Trial

October 12 at 3:01 PM | finance.yahoo.com

HC Wainwright Issues Positive Forecast for Mirum Pharmaceuticals (NASDAQ:MIRM) Stock Price

October 12 at 1:17 PM | marketbeat.com

Mirum Pharmaceuticals, Inc. (MIRM) Discusses Phase 3 EXPAND Study Results for Maralixibat in Cholestatic Pruritus Including Biliary Atresia Transcript

October 12 at 1:00 PM | seekingalpha.com

Mirum Pharmaceuticals' LIVMARLI Study Hits Key Endpoints in Rare Liver Diseases

October 12 at 11:01 AM | marketbeat.com

Mirum Pharmaceuticals, Inc. (MIRM) Discusses Phase 3 EXPAND Study Results for Maralixibat in Cholestatic Pruritus Including Biliary Atresia - Slideshow

October 12 at 10:23 AM | seekingalpha.com

Mirum reports LIVMARLI Phase 3 trial success

October 12 at 9:00 AM | grafa.comG

Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases

October 12 at 9:00 AM | marketscreener.comM

Contrasting Mirum Pharmaceuticals (NASDAQ:MIRM) and Fate Therapeutics (NASDAQ:FATE)

October 12 at 7:44 AM | americanbankingnews.com

Mirum Pharmaceuticals to report Livmarli trial results Monday

October 11, 2026 | seekingalpha.com

Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases

October 11, 2026 | businesswire.com

Royal Bank Of Canada Forecasts Strong Price Appreciation for Mirum Pharmaceuticals (NASDAQ:MIRM) Stock

October 10, 2026 | americanbankingnews.com

Mirum’s AZURE-2 Trial Pits Brelovitug Against Bulevirtide in High-Stakes Hepatitis D Study

October 8, 2026 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

COAG, CGON, ERAS, and MIRM Company Descriptions

CG Oncology NASDAQ:CGON

$61.84 -0.56 (-0.90%)

Closing price 10/14/2026 04:00 PM Eastern

Extended Trading

$61.95 +0.11 (+0.18%)

As of 08:30 AM Eastern

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Hemab Therapeutics NASDAQ:COAG

$29.94 +0.14 (+0.47%)

As of 10/14/2026 04:00 PM Eastern

We are a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. Our mission is to build the leading coagulation company by discovering, developing, and commercializing innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases. Coagulation disorders encompass a broad and heterogeneous group of conditions, and many patients experience significant life-long disease burden due to either a lack of available prophylactic therapies or limitations associated with existing treatment approaches. Our lead asset, sutacimig (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency. Our second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand Disease. We are also advancing multiple preclinical and discovery-stage assets. We estimate that there are approximately an aggregate of 10,000 patients with Glanzmann thrombasthenia and Factor VII deficiency and an aggregate of 120,000 patients with Von Willebrand Disease in the geographies where we intend to commercialize our assets, including the United States, the European Union, Japan, the Gulf Cooperation Council countries and other select regions. With greater disease burden awareness, potential regulatory approvals of new prophylactic options and expanding global reach of these options, we believe the overall number of addressable patients for our clinical-stage assets, and preclinical and discovery stage programs could be greater than we currently estimate. We aim to establish the industry’s leading coagulation franchise through the execution of our “Hemab 2x3 by 2030” strategic roadmap, which is designed to build a franchise consisting of 2 commercial medicines, 2 new late-stage clinical programs, and 2 new early-stage clinical programs by 2030. We have not yet initiated pivotal trials for any of our product candidates, and due to the novel and unproven nature of our programs, their current stage of development and the lack of approved prophylactic therapies to inform endpoint selection and trial design, we may not be able to achieve our strategic goals on the timeline we expect or at all. Our principal executive offices are located in Cambridge, MA.

Erasca NASDAQ:ERAS

$14.70 -0.08 (-0.54%)

Closing price 10/14/2026 04:00 PM Eastern

Extended Trading

$14.71 +0.01 (+0.06%)

As of 08:35 AM Eastern

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Mirum Pharmaceuticals NASDAQ:MIRM

$79.96 +0.34 (+0.43%)

Closing price 10/14/2026 04:00 PM Eastern

Extended Trading

$79.70 -0.26 (-0.33%)

As of 08:41 AM Eastern

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest COAG, CGON, ERAS, and MIRM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest COAG, CGON, ERAS, and MIRM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

COAG, CGON, ERAS, and MIRM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

COAG, CGON, ERAS, and MIRM Company Descriptions

CG Oncology NASDAQ:CGON

Hemab Therapeutics NASDAQ:COAG

Erasca NASDAQ:ERAS

Mirum Pharmaceuticals NASDAQ:MIRM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest COAG, CGON, ERAS, and MIRM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest COAG, CGON, ERAS, and MIRM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

COAG, CGON, ERAS, and MIRM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

COAG, CGON, ERAS, and MIRM Company Descriptions

CG Oncology NASDAQ:CGON

Hemab Therapeutics NASDAQ:COAG

Erasca NASDAQ:ERAS

Mirum Pharmaceuticals NASDAQ:MIRM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools